Skip Navigation

COVID-19 Update


Conditions We Treat: Kidney Cancer

About 30 percent kidney cancers are diagnosed after the disease has spread to other organs. Learn more about how we can help diagnose your kidney cancer and provide you with personalized treatment options.

Active Surveillance for Kidney Cancer

Although the incidence of kidney cancer has increased dramatically over the last few decades, research led by Johns Hopkins urologists is showing many of these patients can be followed safely without the need for immediate surgery. In light of these findings, The Brady Urological Institute began the Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry, following patients with small, localized kidney tumors (4 centimeters or smaller, and confined to the kidney), to avoid surgical intervention.


Kidney Cancer: A Multi-Disciplinary Approach that Saved My Life

Kevin Kiernan was experiencing a twinge in his side and pain. He went to urgent care and learned he had a massive tumor on his kidney that had grown out of the kidney, up the Vena Cava and into his heart. Kevin was told his cancer was life threatening and an extremely aggressive cancer. Kevin reached out to The Johns Hopkins Brady Urological Institute and within 24 hours he had an appointment with Dr. Phil Pierorazio. Dr. Pierorazio worked together with specialists from the Johns Hopkins Kimmel Cancer Center, cardiac surgeons and vascular surgeons to provide Mr. Kiernan with personalized kidney cancer care that ended up saving his life.


The role of active surveillance

Phillip M. Pierorazio, MD

The Management of Small Renal Masses and Kidney Cancer

Earlier detection of small renal masses has led to new treatment options for kidney cancer. Watch Johns Hopkins urologist Phil Pierorazio, M.D., as he discusses advances in the diagnosis and treatment of the small renal mass.

Active Surveillance For Renal Masses: Where Are We In 2016?

Phillip M. Pierorazio, MD, asks the question Active Surveillance For Renal Masses: Where Are We In 2016? at the 2016 annual International Kidney Cancer Symposium.

Phase 3 Perioperative Nivolumab in M0 RCC (PROSPER RCC, ECOG –ACRIN 8143) A UROLOGIST’S PERSPECTIVE

Mohamad E. Allaf, MD,  presents Phase 3 Perioperative Nivolumab in M0 RCC (PROSPER RCC, ECOG –ACRIN 8143) A UROLOGIST’S PERSPECTIVE at the 2016 annual International Kidney Cancer Symposium.

Kidney Cancer: What You Need to Know

kidney cancer
  • Not all growths on the kidney are cancer. About 20 to 30 percent of “suspicious” kidney tumors turn out to be benign.
  • Men are twice as likely as women to develop kidney cancer.
  • Kidney cancer is most commonly diagnosed through CT and MRI scans.
  • Multiple treatment options, including surgery, immunotherapy, targeted therapies and clinical trials, are available to patients with kidney cancer that has spread elsewhere in the body.

Patient Resources

Request an Appointment

Request an appointment with a Johns Hopkins Urology specialist at one of our convenient locations in the Baltimore and Washington, D.C. metropolitan areas.


Why Choose Johns Hopkins for Treatment of Kidney Cancer?

kidney cancer

Our Physicians

Rely on the expertise of our physicians to help manage kidney cancer.

Our Treatments

Our experts have pioneered several kidney cancer therapies, including active surveillance and robotic and minimally invasive surgical techniques.

Our Research

Our discoveries are pointing to better ways of diagnosing and treating kidney cancer. Research suggests that people with small kidney tumors may not need immediate surgery.

back to top button